Principles of Practice from the European Expert Panel on the Contemporary Treatment of Schizophrenia

Providing optimal treatment for people with schizophrenia is a difficult long-term problem for clinicians and healthcare providers. Over the years a variety of approaches to treatment have evolved and, until now, there have been no widely accepted standards for care. To determine the principles underpinning the best practice for schizophrenia treatment, an Expert Panel of European psychiatrists and psychologists has worked to distil current theory, collective practical experiences and published literature into 17 basic Principles of Practice . These are not intended to duplicate or replace local treatment policies or guidelines. Instead, they describe best practice in diagnosis, patient assessment and long-term treatment of schizophrenia as it exists at the beginning of the 21st century and is likely to exist in the near future. The Principles of Practice broadly fall into four main categories: (1) assessment, diagnosis and care provision; (2) treatment in day-to-day practice; (3) building a positive therapeutic alliance; and (4) a long-term clinical commitment. Running through all the Principles are several common threads - the fundamental importance of the therapeutic alliance between the clinician and the patient, the need to plan both for treatment efficacy and avoidance of side-effects and the importance of long-term treatment planning. It is intended that psychiatrists and other healthcare professionals can use the Principles as a benchmark for optimum patient management, and as a tool when negotiating the future of local and national schizophrenia management services. Furthermore, the Principles of Practice represent a first step in the development of a new patient-centred philosophy for the care of people with schizophrenia.

[1]  A. Mitchell,et al.  Cognitive-behavioural therapy for schizophrenia. , 2002, The British journal of psychiatry : the journal of mental science.

[2]  S. Francey,et al.  Cognitively oriented psychotherapy for early psychosis (COPE): a 1-year follow-up. , 2001, The British journal of clinical psychology.

[3]  L. Merinder Patient education in schizophrenia: a review , 2000, Acta psychiatrica Scandinavica.

[4]  L. Dixon,et al.  Update on family psychoeducation for schizophrenia. , 2000, Schizophrenia bulletin.

[5]  S. Kasper,et al.  Dopamine- and serotonin-receptors in schizophrenia: results of imaging-studies and implications for pharmacotherapy in schizophrenia , 1999, European Archives of Psychiatry and Clinical Neuroscience.

[6]  A. Altamura,et al.  HPA axis and cytokines dysregulation in schizophrenia: potential implications for the antipsychotic treatment , 1999, European Neuropsychopharmacology.

[7]  R. Murray,et al.  To what extent does symptomatic improvement result in better outcome in psychotic illness? , 1999, Psychological Medicine.

[8]  J. Hellewell,et al.  Treatment-resistant schizophrenia: reviewing the options and identifying the way forward. , 1999, The Journal of clinical psychiatry.

[9]  N. Tarrier,et al.  Randomised controlled effectiveness trial of a needs-based psychosocial intervention service for carers of people with schizophrenia , 1999, British Journal of Psychiatry.

[10]  S. Roose Tolerability and patient compliance. , 1999, The Journal of clinical psychiatry.

[11]  J. McKellar,et al.  Patient satisfaction and acceptability of long-term treatment with quetiapine. , 1999, International journal of psychiatry in clinical practice.

[12]  S. Patten,et al.  Depression in people with first-episode schizophrenia , 1998, British Journal of Psychiatry.

[13]  R. Tandon,et al.  New atypical antipsychotic medications. , 1998, Journal of psychiatric research.

[14]  R. Tandon,et al.  Do atypical antipsychotic medications favorably alter the long-term course of schizophrenia? , 1998, Journal of psychiatric research.

[15]  D. King Drug treatment of the negative symptoms of schizophrenia , 1998, European Neuropsychopharmacology.

[16]  I. Bitter,et al.  Treatment of schizophrenic disorders: Algorithms for acute pharmacotherapy. , 1997, International journal of psychiatry in clinical practice.

[17]  A. David,et al.  Compliance Therapy: An Intervention Targeting Insight and Treatment Adherence in Psychotic Patients , 1996, Behavioural and Cognitive Psychotherapy.

[18]  Altamura Ac Novel antipsychotics and the problem of clinical stabilization in schizophrenia: are they "stabilizer" rather than typical compounds? , 1996 .

[19]  A. Altamura Novel antipsychotics and the problem of clinical stabilization in schizophrenia: are they “stabilizer” rather than typical compounds? , 1996, International clinical psychopharmacology.

[20]  D. Penn,et al.  Research update on the psychosocial treatment of schizophrenia. , 1996, The American journal of psychiatry.

[21]  P. Hayward,et al.  Compliance therapy in psychotic patients: randomised controlled trial , 1996, BMJ.

[22]  P. Bebbington The content and context of compliance , 1995, International clinical psychopharmacology.

[23]  C. Bell DSM-IV: Diagnostic and Statistical Manual of Mental Disorders , 1994 .

[24]  N. Tarrier,et al.  A Trial of Two Cognitive-Behavioural Methods of Treating Drug-Resistant Residual Psychotic Symptoms in Schizophrenic Patients: I. Outcome , 1993, British Journal of Psychiatry.

[25]  A. Altamura A multidimensional (pharmacokinetic and clinical-biological) approach to neuroleptic response in schizophrenia With particular reference to drug resistance , 1993, Schizophrenia Research.

[26]  John M. Davis,et al.  MAINTENANCE ANTIPSYCHOTIC MEDICATION , 1993 .

[27]  T. Barnes,et al.  THE SIDE-EFFECTS OF ANTIPSYCHOTIC DRUGS. I. CNS AND NEUROMUSCULAR EFFECTS , 1993 .

[28]  W. Iacono,et al.  Establishing the onset of psychotic illness. , 1993, The American journal of psychiatry.

[29]  J. Lieberman,et al.  Duration of psychosis and outcome in first-episode schizophrenia. , 1992, The American journal of psychiatry.

[30]  A. Korten,et al.  Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study. , 1992, Psychological medicine. Monograph supplement.

[31]  A. Rifkin,et al.  Dosage of haloperidol for schizophrenia. , 1991, Archives of general psychiatry.

[32]  S. Marder,et al.  A controlled dose comparison of haloperidol in newly admitted schizophrenic patients. , 1990, Archives of general psychiatry.

[33]  L. Helgason Twenty years’ follow‐up of first psychiatric presentation for schizophrenia: what could have been prevented? , 1990, Acta psychiatrica Scandinavica.

[34]  G Honigfeld,et al.  Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. , 1988, Archives of general psychiatry.

[35]  Martin H. Teicher,et al.  Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. , 1988, Archives of general psychiatry.

[36]  T. Crow,et al.  The Northwick Park Study of First Episodes of Schizophrenia , 1986, British Journal of Psychiatry.